The mechanistic target of rapamycin (mTOR) has a key role in the integration of various physiological stimuli to regulate several cell growth and metabolic pathways 1 . mTOR primarily functions as a catalytic subunit in two structurally related but functionally distinct multi-component kinase complexes, mTOR complex 1 (mTORC1) and mTORC2 (refs 1, 2). Dysregulation of mTOR signalling is associated with a variety of human diseases, including metabolic disorders and cancer 1 . Thus, both mTORC1 and mTORC2 kinase activity is tightly controlled in cells. mTORC1 is activated by both nutrients 3-6 and growth factors 7 , whereas mTORC2 responds primarily to extracellular cues such as growth-factor-triggered activation of PI3K signalling [8] [9] [10] . Although both mTOR and GβL (also known as MLST8) assemble into mTORC1 and mTORC2 (refs 11-15), it remains largely unclear what drives the dynamic assembly of these two functionally distinct complexes. Here we show, in humans and mice, that the K63-linked polyubiquitination status of GβL dictates the homeostasis of mTORC2 formation and activation. Mechanistically, the TRAF2 E3 ubiquitin ligase promotes K63-linked polyubiquitination of GβL, which disrupts its interaction with the unique mTORC2 component SIN1 (refs 12-14) to favour mTORC1 formation. By contrast, the OTUD7B deubiquitinase removes polyubiquitin chains from GβL to promote GβL interaction with SIN1, facilitating mTORC2 formation in response to various growth signals. Moreover, loss of critical ubiquitination residues in GβL, by either K305R/K313R mutations or a melanomaassociated GβL(ΔW297) truncation, leads to elevated mTORC2 formation, which facilitates tumorigenesis, in part by activating AKT oncogenic signalling. In support of a physiologically pivotal role for OTUD7B in the activation of mTORC2/AKT signalling, genetic deletion of Otud7b in mice suppresses Akt activation and Kras-driven lung tumorigenesis in vivo. Collectively, our study reveals a GβL-ubiquitination-dependent switch that fine-tunes the dynamic organization and activation of the mTORC2 kinase under both physiological and pathological conditions.
stimulation at early time points correlated with elevated Gβ L interaction with mTORC2 components SIN1 and RICTOR, and reduced binding to mTORC1 component RPTOR (Fig. 1c, d and Extended Data Fig. 1f-l) . Therefore, Gβ L ubiquitination status may have a physiological role in regulating mTOR complex homeostasis.
Notably, ubiquitinated Gβ L under serum-starved conditions was primarily K63-linked, the levels of which were significantly reduced upon insulin stimulation ( Fig. 2g-i) . Moreover, TRAF2 promoted non-proteolytic K63-linked ubiquitination of Gβ L, without affecting its protein stability in a manner dependent on the TRAF2 recognition motif ( Fig. 1h and Extended Data Fig. 2j-n) .
Furthermore, the dynamic fluctuation of Gβ L ubiquitination in wildtype mouse embryonic fibroblasts (MEFs) upon growth factor stimulation was largely abolished in Traf2 −/− MEFs, accompanied by elevated Akt(phosphorylated (p)S473) and Akt(pS473)-dependent phosphorylation of Foxo1 (ref. 12, 13, 15) , but minimal changes in Akt(pT308) or S6k(pT389) (Fig. 1i , j and Extended Data Fig. 2o, p) . Under normal culture conditions, manipulation of TRAF2 also impacted primarily on AKT(pS473) levels, but minimally on S6K(pT389) or AKT ubiquitination ( Fig. 1k and Extended Data Fig. 2q, r) . Moreover, Gβ L ubiquitination was unresponsive to mTOR inhibition or TNFα stimulation (Extended Data Fig. 2s, t) . Thus, loss of TRAF2-mediated Gβ L ubiquitination largely facilitates the activation of mTORC2, with minimal effects on mTORC1 or PDK1 signalling.
To elucidate further the molecular mechanisms underlying TRAF2-mediated ubiquitination of Gβ L in regulating mTORC2 complex organization and activity, we found that the seventh WD40 motif (WD7) in Gβ L was both necessary and sufficient for Gβ L ubiquitination in cells (Fig. 2a, b) . Furthermore, WD7 mediated the specific interaction of Gβ L with SIN1 (ref. [12] [13] [14] , a unique component of mTORC2, while the adjacent WD6 motif mediated the specific Gβ L interaction with RPTOR (ref. 11), the mTORC1-specific subunit ( Fig. 2c and Extended Data Fig. 3a-c) . Given that mTORC2-, but not mTORC1-associated Gβ L was poorly ubiquitinated (Extended Data Fig. 3d-f) , we reasoned that Gβ L ubiquitination on the WD7 motif by TRAF2 may regulate Gβ L distribution into mTOR complexes. Indeed, depletion of Traf2 elevated mTORC2 complex formation, but reduced mTORC1 abundance. Conversely, ectopic expression of TRAF2 Letter reSeArCH 3 enhanced mTORC1 formation coupled with impaired mTORC2 assembly ( Fig. 2d and Extended Data Fig. 3g-j) .
Next we sought to identify the critical Gβ L ubiquitination sites within WD7, and found that mutating the two conserved lysine residues, K305 and K313, drastically reduced Gβ L ubiquitination levels (Extended Data Fig. 4a-c) . Consistently, CRISPR-mediated introduction of the KRKR mutations into the endogenous MLST8 gene (Gβ L(KRKR)) significantly reduced Gβ L K63-linked ubiquitination in cells, which subsequently enhanced mTORC2 assembly coupled with reduced mTORC1 formation, a phenotype observed upon depleting Traf2 or deleting the TRAF2 binding site in Gβ L (Fig. 2e , f and Extended Data Fig. 4d-i) .
Moreover, TRAF2 suppressed mTORC2 complex formation and mTORC2/AKT signalling in part by increasing Gβ L ubiquitination ( Fig. 2g and Extended Data Fig. 4j, k) . As a result, under physiological conditions such as growth factor stimulation, compared to cells expressing wild-type Gβ L, cells expressing Gβ L(KRKR) displayed enhanced Gβ L interaction with mTORC2 components to activate mTORC2/Akt signalling, but exhibited reduced Gβ L interaction with Rptor and slightly affected S6k(pT389) levels at later time points ( Fig. 2h and Extended Data Fig. 4l, m) .
Hence, Gβ L ubiquitination may provide a molecular switch to govern the balance between mTORC2 and mTORC1 (Fig. 2i) . In doing so, TRAF2-mediated Gβ L ubiquitination on K305/K313 in the WD7 domain precludes SIN1 or RICTOR binding, thereby disrupting mTORC2 complex integrity, thus indirectly favouring RPTOR binding on the adjacent WD6 motif to promote mTORC1 complex formation. However, upon insulin stimulation, loss of Gβ L WD7 ubiquitination allows interaction between Gβ L and SIN1, thereby priming a population of non-ubiquitinated Gβ L to be incorporated into mTORC2, which fine-tunes the dynamic balance of mTOR complexes for optimal response to upstream signalling cues. Importantly, consistent with a previous study 15 , Gβ L is indispensable for mTORC2, but not mTORC1, integrity and activation (Extended Data Fig. 5a ), while the underlying mechanism remains not fully understood 2, 15 . However, reduced Gβ L integration into mTORC1 at early time points of growth stimulation or in cells depleted of Traf2 or expressing Gβ L(KRKR) might be compensated by elevated mTORC1 kinase activity, possibly due to increased phosphorylation of TSC2 by Akt to reduce TSC2 inhibition of mTORC1 21 (Figs 1j, 2h and Extended Data Figs 4l, m and 5b). Notably, reintroducing ubiquitination and SIN1-binding deficient Gβ L(Δ WD7) into MLST8-depleted cells failed to restore AKT(pS473) to confer chemoresistance and transforming capacities (Extended Data Fig. 6a-e) . More importantly, compared to wild-type cells, cells expressing the ubiquitination-deficient Gβ L mutants (Gβ L(PEAA) and Gβ L(KRKR)) displayed elevated AKT(pS473), coupled with increased chemoresistance, colony formation, anchorage-independent growth and tumour growth, while inhibiting AKT activity reversed these malignant phenotypes (Fig. 3a-e and Extended Data Fig. 6f-v) . These data suggest that loss of Gβ L-ubiquitination-mediated promotion of mTORC2 complex formation is physiologically critical for activation of mTORC2/AKT oncogenic signalling, contributing to cellular chemoresistance and tumorigenicity.
In keeping with a possible role of loss of Gβ L ubiquitination in favouring human cancers through elevated mTORC2 signalling , h) , or GβL-depleted A375 cells stably expressing Gβ L or Gβ L(Δ W297) (i). j, k, Growth curve (j) and weight (k) of subcutaneous tumours formed by GβL-depleted A375 cells expressing Gβ L or Gβ L(Δ W297) (mean ± s.d., n = 7 nude mice (j) or 6 tumours (k) per group; * P < 0.05, * * P < 0.01, Student's t-test). For uncropped gels, see Supplementary Fig. 1 . For tumour data, see Source Data for e, j, k.
a Gβ L(Δ W297) mutant missing Gβ L ubiquitination sites (K305 and K313) was identified in melanoma (Fig. 3f , sample ID: TCGA-FS-A1ZZ-06). Gβ L(Δ W297) was poorly ubiquitinated in cells, leading to an elevated formation of mTORC2 complex and increased mTORC2 activity towards phosphorylating S473 of AKT (Fig. 3g-i and Extended Data Fig. 7a-d) . Consequently, Gβ L(Δ W297)-expressing cells displayed enhanced chemoresistance and tumorigenicity, while inhibiting AKT activity attenuated these malignant behaviours (Fig. 3j, k and Extended Data Fig. 7e-m) . Thus, the oncogenic activity of Gβ L(Δ W297) may be partially due to loss of Gβ L-ubiquitinationmediated disruption of mTOR complex homeostasis and aberrant AKT activation.
We went on to identify the potential deubiquitinase(s) (DUBs) that removes ubiquitin chains from Gβ L. To this end, a subset of the ovarian tumour (OTU) family of DUBs has demonstrated specificity towards hydrolysing the K63-linkage 23 . Notably, OTUD7B, but no other OTU DUB family members examined, specifically interacted with Gβ L to remove Gβ L ubiquitination in cells ( Fig. 4a and Extended Data Fig. 8a, b) . Moreover, OTUD7B reduced the levels of K63-, but not K48-linked Gβ L ubiquitination, minimally affecting the half-life of Gβ L protein (Fig. 4b , Extended Data Fig. 8c-f) . Additionally, OTUD7B, but not UCH-L1, a DUB for RPTOR 24 , targeted Gβ L for deubiquitination (Extended Data Fig. 8g-j) . Thus OTUD7B, apart from hydrolysing K11 ubiquitin chains 23, 25, 26 , is also a bona fide DUB that removes K63-linkage polyubiquitination from Gβ L.
In keeping with a role for Gβ L ubiquitination in dictating mTORC2 homeostasis, deletion of Otud7b reduced mTORC2, but elevated mTORC1 formation, leading to impaired activation of mTORC2/Akt signalling ( Consistently, upon growth factor stimulation, the reduction of Gβ L ubiquitination was attenuated upon OTUD7B knockdown (Extended Data Fig. 9a, b) . Reduced Gβ L ubiquitination was largely due to induced binding of OTUD7B to Gβ L, but not loss of TRAF2 binding ( Fig. 4f and Extended Data Fig. 9c-e) . On the other hand, the interaction of UCHL1 and RPTOR was minimally affected by growth factor signalling (Extended Data Fig. 9f ). These results indicate that OTUD7B-mediated deubiquitination, rather than TRAF2-induced ubiquitination is physiologically regulated by growth factor signalling to control Gβ L ubiquitination and mTOR complex homeostasis.
Moreover, polyubiquitin chains on Gβ L are required for its interaction with OTUD7B, largely via the ubiquitin-associated (UBA) domain on OTUD7B, leading to Gβ L deubiquitination and downstream mTORC2/AKT signalling (Extended Data Fig. 9g-n) . In support of this notion, OTUD7B facilitated Gβ L integration into mTORC2, probably through deubiquitinating Gβ L, to elevate AKT(pS473), thereby facilitating chemoresistance and cell growth (Extended Data Fig. 9o-t) . OTUD7B-mediated cleavage of K63-linked polyubiquitin chains on Gβ L appears to be a common mechanism to promote mTORC2/AKT signalling, as knockdown of OTUD7B downregulated AKT(pS473) and conferred chemosensitivity to cancer cells with elevated mTORC2/AKT signalling due to oncogenic events such as PTEN deletion, PIK3CA, EGFR or KRAS mutations (Extended Data Fig. 10a-d) . Consistently, the OTUD7B gene was frequently amplified in various cancers including 
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GβL lung cancers, where high OTUD7B mRNA levels in lung cancers correlated with lower survival probability in a cohort of 1,926 patients (Extended Data Fig. 10e, f) .
Given that binding of p110α subunit to Ras and subsequent activation of PI3K is required for the development and maintenance of Kras-driven lung tumours 27, 28 , we further assessed whether Otud7b-promoted mTORC2/Akt signalling is causally related to Kras-induced lung tumorigenesis. In the Otud7b +/+ background, Kras LA2 mice developed spontaneous lung tumour nodules at the age of 16-23 weeks (Fig. 4g) (Fig. 4k) . These results suggest that Otud7b is required for Kras-driven lung tumour initiation and progression at least partially by facilitating activation of mTORC2/Akt signalling. Collectively, these results reveal a Gβ L polyubiquitination-dependent mechanism governing the integrity of mTORC2. These findings also reveal new regulatory roles of OTUD7B and TRAF2, essential regulators of the NF-κ B pathway 29 , in mTORC2/AKT signalling and cancer biology, in addition to a reported role of OTUD7B in enhancing breast cancer proliferation 30 . Importantly, OTUD7B, rather than TRAF2, appears to be the primary regulatory mechanism to translate growth signals via active cleavage of the K63 polyubiquitin chain on Gβ L, thereby modulating mTORC2 homeostasis under physiological conditions (Fig. 4l) . Pathologically, OTUD7B-mediated activation of mTORC2/AKT signalling may be a critical molecular event downstream of the RAS/PI3K pathway to favour Kras LA2 -driven lung tumorigenesis, suggesting that OTUD7B may be a potential therapeutic target against diseases harbouring hyperactivated PI3K/mTOR signalling such as cancer.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 29 . All the cell lines were routinely tested negative for mycoplasma contamination. Transfection was performed using lipofectamine 2000 reagent as described previously 9, 10 . For serum starvation, 32 h post-transfection, cells were washed with PBS twice and cultured in FBS-free DMEM for 14-16 h. To initiate growth factor signalling, the medium was added with EGF (Sigma E9644, 100 ng ml 31 . The HA-Gβ L(K305R), HA-Gβ L (K313R), HA-Gβ L(K305R/K313R) (KRKR), HA-Gβ L(P265A/E267A) (PEAA), Flag-Myc-OTUD7B(C194A) mutants 29, 32 were constructed using the Site-Directed Mutagenesis Kit (Stratagene) following the manufacturer's instructions. His-Ub, His-Ub(K6R), His-Ub(K11R), His-Ub(K27R), His-Ub(K29R), His-Ub(K33R), His-Ub(K48R), His-Ub(K63R), His-Ub(K0), His-Ub(K48) only and His-Ub(K63) only vectors were provided by P. P. Pandolfi (Beth Israel Deaconess Medical Center, Harvard Medical School). Gβ L shRNA vectors were purchased from GE Healthcare Dharmacon (Clone ID: TRCN0000039758, TRCN0000039759, TRCN0000039760, TRCN0000039761, TRCN0000039762). Lentiviral shRNA vectors depleting human OTUD7B were from an shRNA library targeting human de-ubiquitinating enzymes (OBS Catalogue number: RHS6054), purchased from Thermo Scientific Open Biosystems. The target sequences are OTUD7B shRNA #1: 5′ -CGGCGGAAGGAGAAGTCAA-3′ and OTUD7B shRNA #2: 5′ -ACGTCTTTGTCCTTGCTCA-3′ . Virus packaging and cell infection. For lentiviral shRNA infection, HEK293FT cells were transfected with shGFP or Gβ L shRNA or OTUD7B shRNA plenti-puro vectors, together with packing vectors (Δ 8.9 and VSVG plasmids) using lipofectamine 2000 reagent as previously described 9, 10 . To restore Gβ L expression, Gβ L mutants resistant to shRNA (Gβ L-shRes) were constructed from HA-Gβ L, HA-Gβ L(PEAA) and HA-Gβ L(KRKR) vectors using the following primer sets: 5′ -CAATAGCACCGGCAACTGCTACGTATGGAATCTGACG-3′ (sense) and 5′ -CGTCAGATTCCATACGTAGCAGTTGCCGGTGCTATTG-3′ (antisense). The shRes HA-Gβ L, HA-Gβ L(PEAA) and HA-Gβ L(KRKR) were subcloned into pBabe-hygro retroviral vectors 33 and co-transfected with packaging vectors (Retro-VSVG, JK3, and CMV-TAT plasmids) into HEK293FT cells using lipofectamine 2000 reagent. All the constructs were confirmed by DNA sequencing. The cells were infected with various virus particles and selected with medium containing puromycin and/or hygromycin for at least three days. Ubiquitination assays in cells. Cellular ubiquitination assays were performed as described previously 34 . In brief, HEK293 cells were co-transfected with His-Ub and the indicated vectors for 48 h and lysed in denaturing condition (buffer A: 6 M guanidine-HCl, 0.1 M Na 2 HPO 4 /NaH 2 PO 4 , 10 mM imidazole (pH 8.0)). After sonication, the poly-ubiquitinated proteins were purified by incubation with nickel-nitrilotriacetic acid (Ni-NTA) matrices (QIAGEN) for 3 h at room temperature. Histidine pull-down products were washed sequentially once in buffer A, twice in buffer A/TI mixture (buffer A:buffer TI = 1:3), and once in buffer TI (25 mM Tris-HCl and 20 mM imidazole (pH 6.8)). The poly-ubiquitinated proteins were separated by SDS-PAGE for immunoblot analysis. UB-AQUA/PRM proteomics. HEK293 cells were transfected with CMV-GST-Gβ L and ubiquitin expression constructs. Thirty-two hours post-transfection, the cells were serum starved for 16 h, with or without insulin stimulation, and lysed using Triton buffer for GST pull-down. The GST pull-down products were eluted with glutathione-containing buffer and then subjected to Ubiquitin Absolute Quantification (UB-AQUA) mass spectrometry (MS) analysis of ubiquitin chain linkage. For UB-AQUA/PRM, samples were subject to TCA precipitation. Samples were digested first with Lys-C (in 100 mM tetraethylammonium bromide (TEAB), 0.1% Rapigest (Waters Corporation), 10% (vol/vol) acetonitrile (ACN)) for 2 h at 37 °C, followed by the addition of trypsin and further digested overnight. Digests were acidified with an equal volume of 5% (vol/vol) formic acid (FA) to a pH of approximately 2 for 30 min, dried down, and resuspended in 1% (vol/vol) FA.
UB-AQUA/PRM was performed largely as described previously but with several modifications [35] [36] [37] . A collection of 16 heavy-labelled reference peptides 36 , each containing a single 13 C/ 15 N-labelled amino acid, was produced at Cell Signaling Technologies and quantified by amino acid analysis. UB-AQUA peptides from working stocks (in 5% (vol/vol) FA) were diluted into the digested sample (in 1% (vol/vol) FA) to be analysed to an optimal final concentration predetermined for individual peptide. Samples and AQUA peptides were oxidized with 0.05% hydrogen peroxide for 20 min, subjected to C18 StageTip and resuspended in 1% (vol/vol) FA. MS data were collected sequentially by liquid chromatography (LC)/MS on a Q Exactive mass spectrometer (Thermo Fisher Scientific) coupled with a Famos Autosampler (LC Packings) and an Accela600 LC pump (Thermo Fisher Scientific). Peptides were separated on a 100 μ m i.d. microcapillary column packed with around 0.5 cm of Magic C4 resin (5 μ m, 100 Å; Michrom Bioresources) followed by approximately 20 cm of Accucore C18 resin (2.6 μ m, 150 Å; Thermo Fisher Scientific). Peptides were separated using a 45 min gradient of 3-25% ACN in 0.125% FA with a flow rate of about 300 nl min , maximum injection time of 250 ms, and profile spectrum data type. This scan was followed by 12 targeted MS2 scans selected from a scheduled inclusion list with a 8-min retention time window. Each targeted MS2 scan consisted of high-energy collision dissociation (HCD) with the following parameters: resolution of 17,500, AGC of 1 × 10
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, maximum injection time of 200 ms, isolation window of 1 Th, normalized collision energy (NCE) of 23, and profile spectrum data type. Raw files were searched, and precursor and fragment ions were quantified using Skyline version 3.5 (ref. 38) . Data generated from Skyline were exported into an Excel spreadsheet for further analysis as previously described 36 . Total UB was determined as the average of the total UB calculated for each individual locus, unless specified otherwise. Mass spectrometry analysis. Samples were subjected to reduction (10 mM TCEP) and alkylation (20 mM chloroacetamide) followed by TCA precipitation. Samples were digested overnight at 37 °C with Lys-C and trypsin (in 100 mM TEAB, 0.1% Rapigest, 10% (vol/vol) acetonitrile (ACN)). Digests were acidified with an equal volume of 5% (vol/vol) formic acid (FA) to a pH of approximately 2 for 30 min, dried down, resuspended in 1% (vol/vol) FA before C18 StageTip (packed with Empore C18; 3M Corporation) desalting. Eluted peptide were resuspended in 1% FA and mass spectrometry data were collected using a Qexactive mass spectrometer (Thermo Fisher Scientific, San Jose, CA) with a Famos Autosampler (LC Packings) and an Accela600 liquid chromatography (LC) pump (Thermo Fisher Scientific). Peptides were separated on a 100 μ m inner diameter microcapillary column packed with around 0.5 cm of Magic C4 resin (5 μ m, 100 Å, Michrom Bioresources) followed by about 20 cm of Accucore C18 resin (2.6 μ m, Letter reSeArCH 150 Å, Thermo Fisher Scientific). Peptides were separated using an 80 min gradient of 3 to 35% acetonitrile in 0.125% formic acid with a flow rate of approximately 300 nl min −1
. The scan sequence began with an MS1 spectrum (Orbitrap analysis; resolution 70,000; mass range 300− 1,500 m/z; automatic gain control (AGC) target 1 × 10 6 ; maximum injection time 250 ms). Precursors for MS2 analysis were selected using a Top20 most abundant peptides. MS2 analysis consisted of highenergy collision-induced dissociation (quadrupole ion trap analysis; AGC 1 × 10 5 ; normalized collision energy (NCE) 25; maximum injection time 60 ms; resolution 17,500). Sequest-based identification using a Human UNIPROT database followed by a target decoy-based linear discriminant analysis was used for peptide and protein identification as described 39 . Parameters used for database searching include: 50 p.p.m. Precursor mass tolerance; 0.03 Da product ion mass tolerance; tryptic digestion with up to three missed cleavages; carboxyamidomethylation of Cys was set as a fixed modification, while oxidation of Met was set as variable modifications. Localization of diGly sites used a modified version of the A-score algorithm as described 40, 41 . A-scores of 13 were considered localized. Generation of the GβL KRKR knock-in cell line by CRISPR-Cas9 technology. The GβL KRKR knock-in cell line was generated following the protocol described previously 42 . The sgRNA (5′ -TCCAGCTTCCTCGGACAACC-3′ ) targeting the genomic sequence close to the Gβ L K305/K313 site was designed using the CRISPR design tool (http://crispr.mit.edu) and cloned into GeneArt CRISPR nuclease vector with OFP reporter (Life Technologies, A21174). A 167-nt single-stranded oligodeoxynucleotides (ssODNs) was used as the template with KRKR mutation and a silent change to the PAM site that do not alter the amino acid sequence. The sgRNA construct and the ssODNs were co-transfected into HEK293 cells. Forty-eight hours post-transfection, the OFP-positive cells were enriched by FACS sorting and seeded into a 96-well plate with one cell per well. The genomic DNA of individual clone was extracted using the Quick Extract DNA Extraction Solution (Epicentre, Q09050) and used as the template to amplify the DNA fragment containing the K305/K313 site. The PCR products were cut by BspEI (NEB, R0540L) to screen the potential correct clones. Finally, knock-in mutations were verified by the Sanger sequencing method. The primers for amplification of the genomic DNA were: forward, 5′ -GCAGCTTCCCCTCTGCTG-3′ ; reverse, 5′ -AGGGGAGGGTCTGCTCTG-3′ . ssODNs: 5 ′ -GCACCAGGCAGTCCCGAGGGGTCACAGGCTAGCCCAGCAC ACTGTCATTGAAGGCCAGGCAGACAACAGCCCGCTGGTGGCCGCCA TACTCTCTCCGGATCTCTCCAGTCTCCACACACCAGAGCCGGGCGAGG TTGTCCGAGGAAGCTGGAGGGGGAGATTGTGCA-3′ . Protein half-life assays. To measure the half-life of Gβ L protein in cells, a cycloheximide (CHX)-based assay was performed following our previously described experimental procedures 34 .
Gel-filtration chromatography assays. Traf2
−/− MEFs, GβL KRKR knock-in HEK293 cells, Otud7b −/− MEFs, and corresponding wild-type cells, or GβL-depleted A375 cells stably expressing Gβ L or Gβ L(Δ W297) were cultured in serum-containing medium were washed with phosphate-buffered saline, lysed in 0.5 ml of CHAPS buffer supplemented with protease inhibitors (Complete Mini, Roche) and phosphatase inhibitors (phosphatase inhibitor cocktail set I and II, Calbiochem). Alternatively, HEK293 cells were serum starved for 16 h and stimulated with or without insulin (100 nM) for 15 min, and lysed using CHAPS buffer. The gel filtration chromatography assays were performed as described previously 9 . In brief, whole-cell lysates (WCL) were filtered through a 0.45 μ m syringe filter and protein concentration was adjusted to 8 mg ml −1 with CHAPS buffer. Afterward, 500 μ l of the WCL was injected onto a Superdex 200 10/300 GL column (GE Lifesciences cat. no. 17-5175-01). Chromatography was performed on the AKTA-FPLC (GE Lifesciences cat. no. 18-1900-26) with CHAPS buffer. One column volume of eluates was fractionated with 500 μ l in each fraction, at the elution speed of 0.3 ml min . Aliquots (25 μ l each) of each fraction were resolved by SDS-PAGE gels and detected with indicated antibodies. Immunoblots and immunoprecipitation. CHAPS buffer (40 mM Tris, pH 7.5, 120 mM NaCl, 1 mM EDTA, 0.3% CHAPS) 11, 43 , Triton buffer (40 mM Tris, pH 7.5, 120 mM NaCl, 1 mM EDTA, 1% Triton X-100) or EBC buffer (50 mM Tris, pH 7.5, 120 mM NaCl, 0.5% NP-40) was added with protease inhibitors (Complete Mini, Roche) and phosphatase inhibitors (cocktail set I and II, Calbiochem). When analysing mTOR complex formation, cells were lysed using CHAPS buffer to preserve mTOR complex integrity. Under other experimental conditions, WCL were collected using EBC, CHAPS or Triton buffer as indicated. Protein concentrations were measured using Bio-Rad protein assay kit in a spectrophotometer (Beckman Coulter DU-800). To perform immunoprecipitation, same amounts of WCL were incubated with the primary antibodies (1-2 μ g) for 4 h at 4 °C. The incubation tubes were added with Protein A/G sepharose beads (GE Healthcare) to incubate for 1 h and washed four times with NETN buffer (20 mM Tris, pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5% NP-40) or CHAPS buffer. For western blot analysis, equal amounts of WCL or immunoprecipitate were separated by SDS-PAGE and immunoblotted with indicated antibodies.
Cell viability assays. To examine cell viability, cells were seeded at 3,000 per well in 96-well plates overnight and treated with DMEM medium containing indicated doses of etoposide (Sigma, E1383) or cisplatin (Selleck S1166) for 24 h. The viability was measured using a CellTiter-Glo Luminescent Cell Viability Assay Kit (Promega), following the manufacturer's instructions. Colony formation assays. The indicated tumour cells were plated in six-well plates (300 or 600 cells per well) and maintained for up to 10-12 days. Visible colonies were washed with PBS and fixed with 10% acetic acid/10% methanol for 30 min, and then stained with 0.4% crystal violet/20% ethanol. After washing with distilled water and air-dried, the colonies were quantified and analysed. Soft agar assays. The anchorage-independent growth capacity of tumour cells was examined by soft agar assays, as described previously 9, 10 . In brief, each well of sixwell plates was coated with the bottom layer noble agar (0.8%). The single tumour cells were seeded into the top layer medium containing 0.4% agar. Specifically, 3 × 10 4 OVCAR5 cells or 1 × 10 4 A375 cells were plated in the top layer of each well. The wells were added with 500 μ l complete DMEM medium every 3 days. Four weeks later, the cells were stained with iodonitrotetrazolium chloride and visible colonies were counted. The assays were performed in triplicates. Xenograft assays in nude mice. All animal experiments were approved by the Beth Israel Deaconess Medical Center IACUC Committee review board. GβL-depleted OVCAR5 cells stably expressing HA-Gβ L or HA-Gβ L(KRKR) were mixed with matrigel (1:1) and inoculated into the flank of female nude mice (2.5 × 10 6 cells per injection, 6 mice for each group). Alternatively, Gβ L-depleted A375 cells stably expressing HA-Gβ L or HA-Gβ L(Δ W297) were injected subcutaneously into female nude mice (5 × 10 6 cells per mice and 7 mice for each cell line). After tumour establishment, the palpable xenograft nodules were measured for the longest diameter (L) and the shortest diameter (W) every three days using a calliper. The tumour volumes were calculated with the formula: L × W 2 × 0.5. After indicated days, the mice were killed humanely. None of the xenograft tumours reached the maximal tumour volume permitted by the institutional IACUC Committee. The xenograft tumours were dissected and weighted. Genetic knockout mouse models. Otud7b −/− mice were generated in B6.129sv genetic background and subsequently backcrossed for four generations to the C57BL/6 background 29 . Kras LA2 mice (in B6.129s2 background) were described previously 44 and provided by the NCI Mouse Repository. The Kras LA2 mice develop tumours in the lung as a result of spontaneous recombination that generates the oncogenic Kras mutant Kras
G12D
.
Otud7b
+/− heterozygous mice were crossed with Kras LA2 mice to generate age-matched Otud7b and Otud7b
−/−
Kras LA2 mice killed humanely at the indicated ages for analyses of lung tumours. Following perfusion with PBS, the lungs were removed and fixed in 10% phosphate-buffered formalin (pH 7.4) for histology analyses. For the survival study, Otud7b +/+ and Otud7b −/− mice with Kras G12D were housed in the animal core facility and the monitored every three days for the indicated time period to calculate survival rate. Haematoxylin and eosin (H&E)-stained lung tissue slides were analysed for tumour numbers and size. Total tissue lysates from the lung or dissected tumours were also prepared and subjected to IB assays. Survival analysis of lung cancer patients. Kaplan-Meier survival curves were generated using the Kaplan-Meier Plotter website for lung cancer (Version 2015, http://kmplot.com) 45 and statistical significance was determined by the log-rank test. Gene expression and patient survival data were downloaded from public databases including Gene Expression Omnibus (GEO), European Genome-Phenome Archive (EGA), and The Cancer Genome Atlas (TCGA). Statistics. The majority of experiments were repeated at least three times to obtain data for indicated statistical analyses. No statistical method was used to calculate sample size. Group variation was not estimated before experiments. The experiments were not randomized in the animal studies and investigators were not blind during experiments and outcome assessment. For western blotting data, representative images from 3-5 biological replicate experiments were shown. For quantification analysis, the original western blot images were quantified using ImageJ software to measure the intensity of some key blots for statistical analysis. The number of mice per group was described in the corresponding figure legends and none of the animals was excluded from the experiment. All quantitative data were presented as mean ± s.d. Results were analysed by a two-tailed unpaired or paired Student's t-test or two-way ANOVA, as appropriate. * P < 0.05; * * P < 0.01; * * * P < 0.001. For survival analysis, the Kaplan-Meier survival curves were compared using the log-rank test. Data availability. Uncropped images for immunoblots are provided in Supplementary  Fig. 1 . Mouse model data are also provided in the Source Data. All other relevant data are available from the corresponding author upon reasonable request.
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Extended Data Figure 1 | The polyubiquitination status of GβL and mTORC2 kinase formation is regulated by upstream physiological stimuli. a-c, The polyubiquitination status of Gβ L is reduced in response to growth factor stimulation. Immunoblot (IB) analysis of wholecell lysates (WCL) or Ni-NTA pull-down products under denaturing conditions derived from HEK293 cells transfected with His-Ub together with (a, c) or without (b) HA-Gβ L vector. Cells were serum starved for 16 h and treated with insulin (100 nM) or Dulbecco's phosphate-buffered saline (DPBS) for 30 min (a, c) , or EGF (100 ng ml −1 ) for 16 min (b) before harvesting. d, e, Unlike Gβ L, polyubiquitination of RPTOR is minimally affected by growth signalling induction. IB analysis of WCL or Ni-NTA pull-down products under denaturing conditions derived from HEK293 cells transfected with HA-RPTOR and His-Ub constructs. Thirty-two hours post-transfection, cells were subjected to serum starvation for 16 h, and then exposed to insulin (100 nM) (d) or EGF (100 ng ml −1 ) (e) at indicated time points before harvesting. f, Quantification results from three independent experiments showing fold differences of endogenous Gβ L binding to SIN1, RICTOR and Rptor in cells in response to insulin stimulation, as indicted in Fig. 1c . Data are mean ± s.d. The intensity of each blot generated using ImageJ software were analysed by twotailed paired Student's t-test, * P < 0.05, * * P < 0.01. g, The assembly of endogenous mTORC1 and mTORC2 responds to physiological growth factor stimulation. IB analysis of Gβ L immunoprecipitate or WCL derived from HEK293 cells serum starved for 16 h, then stimulated with EGF (100 ng ml −1 ), and lysed at indicated time points using CHAPS buffer for immunoprecipitation and IB analysis. Rabbit IgG antibody was used as negative control for Gβ L immunoprecipitation. For quantification analysis, levels were arbitrarily set at 1.0 at the 0 min time point. h-j, Growth factor stimulation enhances mTORC2, but inhibits mTORC1 formation at early time points. IB analysis of HA immunoprecipitate or WCL derived from HEK293 cells transfected with HA-mTOR (h), HA-RPTOR (i), or HA-RICTOR (j) constructs. Thirty-two hours post-transfection, cells were serum starved for 16 h, then stimulated with insulin (100 nM), and lysed at indicated time points using CHAPS buffer for immunoprecipitation and IB analysis. k, Polyubiquitination of Gβ L inversely correlates with mTORC2 integrity and activity in response to EGF stimulation. IB analysis of WCL or Ni-NTA pull-down products under denaturing conditions derived from HEK293 cells transfected with HA-Gβ L and His-Ub constructs. Thirtytwo hours post-transfection, cells were subjected to serum starvation for 16 h, then treated with EGF (100 ng ml −1 ) for indicated time points, lysed for HA immunoprecipitation or His pull-down assays and IB analysis. l, Transient insulin stimulation increases the relative abundance of endogenous mTORC2, but reduces mTORC1 formation in cells. HEK293 cells were subjected to serum starvation for 16 h and treated with or without insulin (100 nM) for 15 min, and lysed using CHAPS buffer. WCL was filtered and run through an FPLC Superdex 200 column. Five hundred microlitres of elute was collected for each fraction and a 1/20 volume of each fraction was resolved on SDS-PAGE and subjected to IB analysis. m, Gβ L polyubiquitination linkage was examined by transfecting Histagged wild-type (WT) and indicated KR ubiquitin mutants together with HA-Gβ L into HEK293 cells, followed by IB analysis of Ni-NTA pull-down products and WCL. n, Polyubiquitination of Gβ L could largely be detected in cells transfected with wild-type ubiquitin and lysine-63-only ubiquitin (K63 only), but not lysine-48-only ubiquitin mutant (K48 only) constructs. IB analysis of Ni-NTA pull-down products and WCL derived from HEK293 cells transfected with HA-Gβ L and wild-type His-Ub or mutant constructs as indicated. For uncropped gels, see Supplementary Fig. 1 . 

Extended Data Figure 3 | TRAF2 promotes polyubiquitination of GβL at the WD7 motif, a specific SIN1-interacting domain, to impair the assembly of mTORC2 kinase. a, b, Gβ L utilizes different WD40 motifs to interact with the two distinct mTOR complexes. Specifically, the WD6 motif is the major Gβ L domain interacting with the unique mTORC1 subunit, RPTOR, while the WD7 motif primarily binds a mTORC2-specific subunit, SIN1 in cells. IB analysis of WCL and GST pull-down products derived from HEK293 cells transfected with HA-RPTOR (a) or HA-SIN1 (b) constructs, together with indicated GST-Gβ L mammalian expression vectors. c, A schematic illustration showing specific binding of RPTOR to the WD6 domain of Gβ L to be incorporated into mTORC1, and binding of SIN1 to the WD7 motif of Gβ L to promote mTORC2 formation. d, A schematic model showing the experimental procedures of a sequential pull-down assay, which is performed to detect the existence of Gβ L ubiquitin moieties in either GST-purified mTORC1 or mTORC2. e, Detection of ubiquitinated Gβ L species in GST-purified mTORC1, but not mTORC2. HEK293 cells were transfected with either GST-SIN1 or GST-Rptor expression constructs, together with His-Gβ L and HA-Ub vectors. Forty-eight hours post-transfection, cells were harvested in CHAPS buffer to specifically pull down the intact mTORC1 or mTORC2 from cell lysates with GST-conjugated beads. The GST pull-down products were eluted using glutathione (GSH)-containing buffer and the elutes were subjected to second round of His pull-down assays in denaturing condition. Afterwards, the resulting samples were resolved on SDS-PAGE and subjected to IB analysis to detect the ubiquitination status of mTORC1-and mTORC2-associated Gβ L, respectively. f, Gβ L is largely ubiquitinated in GST-purified mTORC1, but not mTORC2. HEK293 cells were transfected with either GST-SIN1 or GST-Rptor constructs, together with His-Ub vector. Following a similar protocol as described in e, His pull-down products and WCL were subjected to IB analysis of Gβ L ubiquitin moieties in either mTORC1 or mTORC2. g, Quantification results from three independent experiments showing fold differences of endogenous Gβ L binding to Sin1, Rictor and Rptor in Traf2 +/+ and Traf2 −/− MEFs, as indicated in Fig. 2d (mean ± s. d., * P < 0.05, * * P < 0.01, paired Student's t-test). h, IB analysis of WCL and HA immunoprecipitate derived from Traf2 +/+ and Traf2 −/− MEFs transfected with HA-Gβ L or empty vector (EV) as a negative control. i, Deletion of Traf2 increases the formation of endogenous mTORC2, meanwhile reduces endogenous mTORC1 formation. Traf2 +/+ and Traf2 −/− MEFs in normal culture medium were lysed using CHAPS buffer. WCL was fractionated through an FPLC Superdex 200 column. Five hundred microlitres of eluate was collected for each fraction and a 1/20 volume of each fraction was resolved on SDS-PAGE for IB analysis. j, TRAF2 promotes Gβ L interaction with RPTOR, but inhibits Gβ L-SIN1 binding in an E3-ligase-activitydependent manner. IB analysis of WCL and HA immunoprecipitate derived from HEK293 cells transfected with HA-Gβ L, Myc-RPTOR, Flag-SIN1, together with increasing doses of wild-type TRAF2 or the activity-deficient TRAF2(Δ RING) mutant construct. For uncropped gels, see Supplementary Fig. 1 .
Extended Data Figure 4 | Deficiency in GβL ubiquitination at K305/ K313 of the WD7 domain promotes mTORC2 formation and kinase activity in cells. a, A schematic diagram showing two evolutionarily conserved lysine residues (K305 and K313) within the WD7 domain of Gβ L. b, Mass spectrometry analysis to identify K305 as one of the major Gβ L ubiquitination residues within the WD7 domain of Gβ L in cells. HEK293 cells were transfected with CMV-GST-Gβ L and ubiquitin expression constructs. Forty-eight hours post-transfection, cells were lysed using Triton buffer for GST pull down. The GST pull-down products were eluted with GSH-containing buffer and then subjected to mass spectrometry analysis of ubiquitination sites. The recovered Gβ L peptide and the ubiquitination site (K305) were highlighted in red. c, Mutating key lysine residues within the WD7 domain of Gβ L abolishes Gβ L ubiquitination in cells. Polyubiquitination of Gβ L in HEK293 cells was examined by transfecting the indicated HA-Gβ L constructs with His-Ub, followed by IB analysis of WCL and Ni-NTA pull-down products under denaturing conditions. d, Sequencing of PCR products from genomic DNA demonstrates the introduction of A to G substitution at the codon encoding K305 and K313 of Gβ L gene in a GβL KRKR knock-in HEK293 cell line generated by CRISPR-mediated gene editing. e, Loss of Gβ L ubiquitination leads to elevated Gβ L binding to mTORC2 components, and reduced Gβ L binding to mTORC1 components in cells. IB analysis of WCL and HA immunoprecipitate derived from HEK293 cells transfected with indicated Gβ L plasmids. f, GβL KRKR knock-in cells, compared to wild-type cells, display an increased formation of endogenous mTORC2 and a reduced formation of endogenous mTORC1. HEK293 cells harbouring wild-type Gβ L, or ubiquitination-deficient GβL KRKR were lysed using CHAPS buffer. The WCL was run through an FPLC Superdex 200 column to collect fractionated cell eluates. A 1/20 volume of each fraction was subjected to IB analysis. g, Loss of ubiquitination of endogenous Gβ L promotes mTORC2 formation in CHAPS and EBC buffer, but not Triton buffer. IB analysis of Gβ L immunoprecipitate derived from GβL KRKR knock-in or wild-type HEK293 cells lysed using indicated buffers for immunoprecipitation. The resulting samples were resolved on SDS-PAGE for IB analysis. IB result of WCL prepared using Triton buffer were shown as input. h, Mutating the specific TRAF2 binding site in Gβ L promotes Gβ L integration into mTORC2, but inhibits its integration into mTORC1.
IB analysis of WCL and HA immunoprecipitate derived from HEK293 cells transfected with HA-Gβ L or the TRAF2-non-interacting Gβ L(PEAA) mutant construct. −/− MEFs and wild-type MEFs were depleted of endogenous Gβ L using lentirivus-medicated delivery of short hairpin RNAs (shRNAs) targeting Gβ L and then reintroduced with Gβ L and Gβ L(KRKR) using pBabe-retroviral expression system. The kinase activity of mTORC2/Akt oncogenic signalling in these stable cell lines was analysed by IB analysis of WCL. l, Quantification results for fold differences of Gβ L binding to Sin1, Rictor and Rptor, or the Akt(pS473) levels, in Gβ l −/− MEFs stably expressing Gβ L or the Gβ L(KRKR) mutant at the indicated time points of insulin stimulation, as indicated in Fig. 2h . Data from three independent experiments were presented as mean ± s.d. The intensity of each blot generated using ImageJ software were analysed by paired Student's t-test, * P < 0.05, * * P < 0.01. m, Gβ L polyubiquitination status dictates the dynamic assembly of mTOR complexes in response to EGF stimulation. As such, deficiency in Gβ L polyubiquitination results in elevated mTORC2 formation and elevated downstream Akt activation. IB analysis of WCL and HA immunoprecipitate derived from Gβ l −/− MEFs stably expressing HA-Gβ L or the ubiquitination-deficient HA-Gβ L(KRKR) mutant that were generated by retroviral infection, followed by serum starvation for 16 h and exposure to EGF (100 ng ml −1 ) before harvesting using CHAPS buffer. For uncropped gels, see Supplementary Fig. 1 .
